



Contents lists available at ScienceDirect

## Chinese Chemical Letters

journal homepage: [www.elsevier.com/locate/ccllet](http://www.elsevier.com/locate/ccllet)

## Editorials

The 3<sup>rd</sup> Xihua Chemistry and Biomedicine Forum

Serious diseases, particularly cancer, consistently pose significant threats to both national health and economic development [1]. The cancer diagnosis methods such as fluorescent probes [2,3], as well as treatment techniques including photodynamic treatments [4] and targeted drugs [5] have attracted much attention in recent years. The development and practical application of these methods have become focal points within research works. Based on this, the 3<sup>rd</sup> Xihua Chemistry and Biomedicine Forum (XHCBF) was successfully convened by Xihua University in Chengdu from 3 to 6 July, 2023.

XHCBF serves as an academic platform for experts, scholars and students, aimed at deepening research insights, fostering exchange and collaboration, and accelerating interdisciplinary development across chemistry, medicine, biology, materials and related disciplines. XHCBF was established in Chengdu in 2021 by Xiaoqi Yu, together with Cheng Yang, Zhenju Jiang, Zhouyu Wang and Leyong Wang. The name of the forum "Xihua" carries three meanings: (1) The forum would be held in the beautiful Xihua University; (2) A representation of western China, hoping to form a brand and promote the development of chemical and biopharmaceutical industry in western China; (3) To foster connections with scientists in diverse regions within China. The Editorial Board for organic chemistry of *Chin. Chem. Lett. (CCL)* played a pivotal role in the preparation of the conference, with their guidance and involvement proving instrumental in the success of the 1<sup>st</sup> XHCBF.

The 2<sup>nd</sup> XHCBF was held in August 2022, when it was a critical period to fight against the COVID-2019 pandemic. Under the guidance of Prof. Xiaoqi Yu and Prof. Zhouyu Wang, the organizing committee surmounted various challenges to collaboratively present the second forum alongside the Asymmetric Synthesis and Chiral technology Key Laboratory of Sichuan Province. The theme of the second forum was around Fine Chemistry and

Green Synthesis. The success of the last two forum gradually increased the influence of the forum and improve its scholarly platform.

Therefore, the 3<sup>rd</sup> XHCBF continued its tradition in Chengdu from 3 to 6 July, 2023. The theme of this forum was the Diagnosis and Treatment of Diseases. Prof. Zhouyu Wang and her team organized the forum, with co-hosting support from the Sichuan Engineering Research Center for Molecular Targeted Diagnostic & Therapeutic Drugs, Asymmetric Synthesis and Chiral Technology Key Laboratory of Sichuan Province, Research and Application of Small Organic Chiral Molecules Key Laboratory of Yibin City, and Experimental Teaching Center of Chemistry (Xihua University)-Sichuan Experimental Teaching Demonstration Center (Fig. 1). Academician Fen-er Chen delivered the opening speech for the forum. The forum featured 20 invited talks, presenting the latest research findings spanning the various areas of fluorescent probes, photodynamic therapies and targeted drugs.

In addition, the forum also organized sub-forums tailored for young teachers and graduate students, thereby fostering a robust platform for communication and exchange amongst them. The sustainable increase in attendance well reflects the growing influence of chemistry and biomedicine in China, with a great number of researchers engaging in this vibrant Diagnosis and Treatment of Diseases field. We express our appreciations to all lecturers whose exceptional presentations enriched the forum, as well as to the scholars and graduate students whose attendance contributed to its success.

Lastly, we express our sincere appreciations to CCL. The XHCBF conference committee and Editorial Board of CCL have established a strategic cooperation relationship, envisioning a series of interconnected academic activities spanning diverse fields.



Fig. 1. The participants of 3<sup>rd</sup> Xihua Chemistry and Biomedicine Forum.

Yahui Zhang, Zhouyu Wang\*

Department of Chemistry, School of Science, Xihua University,  
Chengdu 610039, China  
Sichuan Engineering Research Center for Molecular Targeted  
Diagnostic & Therapeutic Drugs, Chengdu 610039, China  
Asymmetric Synthesis and Chiral Technology Key Laboratory of  
Sichuan Province, Chengdu 610039, China

Leyong Wang\*

Department of Chemistry, School of Science, Xihua University,  
Chengdu 610039, China  
Jiangsu Key Laboratory of Advanced Organic Materials, School of  
Chemistry and Chemical Engineering, Nanjing University, Nanjing  
210023, China

Xiaoqi Yu  
Department of Chemistry, School of Science, Xihua University,  
Chengdu 610039, China  
Sichuan Engineering Research Center for Molecular Targeted  
Diagnostic & Therapeutic Drugs, Chengdu 610039, China  
Asymmetric Synthesis and Chiral Technology Key Laboratory of  
Sichuan Province, Chengdu 610039, China

\*Corresponding authors.

E-mail addresses: zhouyuwang77@163.com (Z. Wang),  
lywang@nju.edu.cn (L. Wang)

Received 26 July 2023

Revised 21 August 2023

Accepted 24 August 2023

Available online 26 August 2023

## References

- [1] R.Q. Yang, P.Y. Wang, K.L. Lou, et al., *Adv. Sci.* 9 (2022) e2104728.
- [2] J. Ouyang, L.H. Sun, F. Zeng, S.Z. Wu, *Coord. Chem. Rev.* 458 (2022) 214438.
- [3] J. Xing, Q.Y. Gong, R.F. Zou, et al., *Chin. Chem. Lett.* 34 (2023) 107786.
- [4] P.C. Lo, M.S. Rodriguez-Morgade, R.K. Pandey, et al., *Chem. Soc. Rev.* 49 (2020) 1041–1056.
- [5] Y. Zhang, H. Xia, M. Yang, et al., *Chin. Chem. Lett.* 34 (2023) 108197.